Jalpa Shah

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma

K. Nagashima, D. Newton, D. Scudiero, 2012, PloS one.

Correction: Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma

K. Nagashima, D. Newton, D. Scudiero, 2012, PLoS ONE.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.

L. Esserman, J. Lewicki, A. Gurney, 2013 .

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .